WO2009080017A3 - Markersequenzen für neurodegenerative erkrankungen und deren verwendung - Google Patents

Markersequenzen für neurodegenerative erkrankungen und deren verwendung Download PDF

Info

Publication number
WO2009080017A3
WO2009080017A3 PCT/DE2008/002144 DE2008002144W WO2009080017A3 WO 2009080017 A3 WO2009080017 A3 WO 2009080017A3 DE 2008002144 W DE2008002144 W DE 2008002144W WO 2009080017 A3 WO2009080017 A3 WO 2009080017A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative diseases
marker sequence
marker sequences
relates
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2008/002144
Other languages
English (en)
French (fr)
Other versions
WO2009080017A2 (de
Inventor
Heike GÖHLER
Helmut E. Meyer
Katrin Marcus
Axel Kowald
Florian Tribl
Manfred Gerlach
Peter Riederer
Angelika Lueking
Christian Scheer
Jens Beator
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagen GmbH
Original Assignee
Protagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagen GmbH filed Critical Protagen GmbH
Priority to US12/809,831 priority Critical patent/US20110184375A1/en
Priority to EP08864285A priority patent/EP2222880A2/de
Priority to AU2008340851A priority patent/AU2008340851A1/en
Priority to CA2710401A priority patent/CA2710401A1/en
Publication of WO2009080017A2 publication Critical patent/WO2009080017A2/de
Publication of WO2009080017A3 publication Critical patent/WO2009080017A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft neue Markersequenzen für neurodegenerative Erkrankungen und deren diagnostische Verwendung samt einem Verfahren zum Screenen von potentiellen Wirkstoffen für neurodegenerative Erkrankungen mittels dieser Markersequenzen. Ferner betrifft die Erfindung eine diagnostische Vorrichtung enthaltend solche Markersequenzen für neurodegenerative Erkrankungen, insbesondere ein Proteinbiochip und dessen Verwendung.
PCT/DE2008/002144 2007-12-21 2008-12-22 Markersequenzen für neurodegenerative erkrankungen und deren verwendung Ceased WO2009080017A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/809,831 US20110184375A1 (en) 2007-12-21 2008-12-22 Marker sequence for neurodegenerative diseases and the use thereof
EP08864285A EP2222880A2 (de) 2007-12-21 2008-12-22 Markersequenzen für neurodegenerative erkrankungen und deren verwendung
AU2008340851A AU2008340851A1 (en) 2007-12-21 2008-12-22 Marker sequence for neurodegenerative diseases and the use thereof
CA2710401A CA2710401A1 (en) 2007-12-21 2008-12-22 Marker sequences for neurodegenerative diseases and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007062847.3 2007-12-21
DE102007062847A DE102007062847A1 (de) 2007-12-21 2007-12-21 Markersequenzen für neurodegenerative Erkrankungen und deren Verwendung

Publications (2)

Publication Number Publication Date
WO2009080017A2 WO2009080017A2 (de) 2009-07-02
WO2009080017A3 true WO2009080017A3 (de) 2009-10-29

Family

ID=40512283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2008/002144 Ceased WO2009080017A2 (de) 2007-12-21 2008-12-22 Markersequenzen für neurodegenerative erkrankungen und deren verwendung

Country Status (6)

Country Link
US (1) US20110184375A1 (de)
EP (1) EP2222880A2 (de)
AU (1) AU2008340851A1 (de)
CA (1) CA2710401A1 (de)
DE (1) DE102007062847A1 (de)
WO (1) WO2009080017A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2698437A1 (en) * 2007-09-03 2009-03-12 Protagen Ag Marker sequences for rheumatoid arthritis and use thereof
EP2483694A1 (de) * 2009-10-01 2012-08-08 Protagen AG Biomarker für morbus alzheimer
EP2441848A1 (de) * 2010-10-12 2012-04-18 Protagen AG Markersequenzen für systemischer Lupus Erythematodes und deren Verwendung
EP2487251A1 (de) * 2011-02-13 2012-08-15 Protagen AG Markersequenzen für die Diagnose von Prostatakarzinom und deren Verwendung
CN108034707B (zh) * 2017-12-06 2019-01-08 北京泱深生物信息技术有限公司 Spag7基因在制备老年痴呆诊断制剂中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1477571A1 (de) * 2003-05-16 2004-11-17 Eppendorf AG Bestimmung von einem allgemeinen dreidimensionalen Zellstatus durch mehrfache Genexpressionsanalyse auf Mikroarrays
JP2005132738A (ja) * 2003-10-28 2005-05-26 Protein Express:Kk アルツハイマー病のタンパク質分子レベルにおける検出方法
US20050287544A1 (en) * 2003-12-01 2005-12-29 Francois Bertucci Gene expression profiling of colon cancer with DNA arrays
WO2006134390A2 (en) * 2005-06-17 2006-12-21 Randox Laboratories Ltd Method for diagnosing neurodegenerative disease
US20070281299A1 (en) * 2004-01-19 2007-12-06 Youdim Moussa B Diagnostic Test For Parkinson's Disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE282717T1 (de) 1998-04-30 2004-12-15 Max Planck Gesellschaft Neuartiges verfahren zur identifizierung von klonen mit einer gewünschten biologischen eigenschaft, ausgehend von einer expressionsgenbank
JP2002513589A (ja) 1998-04-30 2002-05-14 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 再アレー化を伴う、発現ライブラリーのクローンを選択するための新規方法
US7960334B2 (en) * 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
DE602004028513D1 (de) * 2003-12-23 2010-09-16 Mount Sinai Hospital Corp Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1477571A1 (de) * 2003-05-16 2004-11-17 Eppendorf AG Bestimmung von einem allgemeinen dreidimensionalen Zellstatus durch mehrfache Genexpressionsanalyse auf Mikroarrays
JP2005132738A (ja) * 2003-10-28 2005-05-26 Protein Express:Kk アルツハイマー病のタンパク質分子レベルにおける検出方法
US20050287544A1 (en) * 2003-12-01 2005-12-29 Francois Bertucci Gene expression profiling of colon cancer with DNA arrays
US20070281299A1 (en) * 2004-01-19 2007-12-06 Youdim Moussa B Diagnostic Test For Parkinson's Disease
WO2006134390A2 (en) * 2005-06-17 2006-12-21 Randox Laboratories Ltd Method for diagnosing neurodegenerative disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURKLEN T S ET AL: "The creatine kinase/creatine connection to alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine deposits", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY 2006 US, vol. 2006, 2006, XP002526523, ISSN: 1110-7243 1110-7251 *
JIN J ET AL: "Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease", MOLECULAR BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 134, no. 1, 24 March 2005 (2005-03-24), pages 119 - 138, XP025297394, ISSN: 0169-328X, [retrieved on 20050324] *
THOMPSON R J ET AL: "Radioimmunoassay of brain-type creatine kinase-BB isoenzyme in human tissues and in serum of patients with neurological disorders", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 47, no. 2, 1 August 1980 (1980-08-01), pages 241 - 254, XP024296682, ISSN: 0022-510X, [retrieved on 19800801] *

Also Published As

Publication number Publication date
US20110184375A1 (en) 2011-07-28
CA2710401A1 (en) 2009-07-02
DE102007062847A1 (de) 2009-12-31
WO2009080017A2 (de) 2009-07-02
AU2008340851A1 (en) 2009-07-02
EP2222880A2 (de) 2010-09-01

Similar Documents

Publication Publication Date Title
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2012049225A3 (de) Markersequenzen für systemischer lupus erythematodes und deren verwendung
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2006127899A3 (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
WO2009021754A3 (en) Monospecific and multispecific antibodies and method of use
WO2007139849A3 (en) Modified nucleic acid nanoarrays and uses therefor
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
IL205398A0 (en) New antibodies specific of the ?? - amyloid peptides and their uses as diagnostic agents or drugs
DK1868600T3 (da) Spirocyklisk cyclohexanderivat til behandling af stofafhængighed
WO2013093115A3 (de) Markersequenzen für brustkrebs und deren verwendung
EP4467136A3 (de) Antagonisten von kalziumkanälen vom typ cav2.3 r zur behandlung von neurodegenerativen erkrankungen
WO2013116668A3 (en) Diagnostic peptides for lyme disease
WO2011112566A3 (en) Basigin binding proteins
WO2013087929A3 (de) Verfahren zur identifizierung von markersequenzen für gynäkologisches malignom
WO2009156090A3 (de) Insektizide schwefel-derivatisierte 1-azinylpyrazole
EA200900261A1 (ru) Применение эсцина
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2010000874A3 (de) Markersequenzen für prostataentzündungserkrankungen, prostatakarzinom und deren verwendung
WO2010000089A8 (en) Stat3 and tyk2 as drug targets for neurodegenerative diseases
WO2010129048A3 (en) Therapeutic compounds
WO2009025300A1 (ja) イミュノグロブリン結合能を有するペプチド
IL172297A0 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis iii
WO2012042062A3 (de) Markersequenzen für multiple sklerose und deren verwendung
WO2009030226A3 (de) Markersequenzen für rheumatoide arthritis und deren verwendung
WO2010000851A3 (en) Methods for modulating angiogenesis via dystrophin dp71

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08864285

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2710401

Country of ref document: CA

Ref document number: 1307/MUMNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008864285

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008340851

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008340851

Country of ref document: AU

Date of ref document: 20081222

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12809831

Country of ref document: US